A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D [bidaily] and Q.I.D [once daily] Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2012
At a glance
- Drugs AZD 6370 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 10 Jan 2012 Last checked against ClinicalTrials.gov record.
- 02 Dec 2010 Actual initiation date changed from (Oct 2007) to (Feb 2008) as reported by ClinicalTrials.gov.
- 28 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History